Literature DB >> 10516076

Minimal incidence of serum antibodies reactive with intact primary isolate virions in human immunodeficiency virus type 1-infected individuals.

L A Cavacini1, J E Peterson, E Nappi, M Duval, R Goldstein, K Mayer, M R Posner.   

Abstract

Immunoglobulin G reactive with primary isolate virions was detected in 36% of serum samples from individuals infected with human immunodeficiency virus type 1. Of these individuals, serum samples from only 7% captured significant quantities of virus. Virion-specific antibody correlated with CD4 counts and, of more significance, primary isolate neutralization. Further dissection of this response should lead to the identification of antibodies and antigenic epitopes for vaccine purposes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10516076      PMCID: PMC113002     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Effect of antibody valency on interaction with cell-surface expressed HIV-1 and viral neutralization.

Authors:  L A Cavacini; C L Emes; J Power; M Duval; M R Posner
Journal:  J Immunol       Date:  1994-03-01       Impact factor: 5.422

2.  Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody.

Authors:  L A Cavacini; C L Emes; J Power; F D Desharnais; M Duval; D Montefiori; M R Posner
Journal:  J Immunol       Date:  1995-10-01       Impact factor: 5.422

3.  Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding.

Authors:  M Thali; J P Moore; C Furman; M Charles; D D Ho; J Robinson; J Sodroski
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

4.  Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding.

Authors:  R Wyatt; J Moore; M Accola; E Desjardin; J Robinson; J Sodroski
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

5.  Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions.

Authors:  R Wyatt; N Sullivan; M Thali; H Repke; D Ho; J Robinson; M Posner; J Sodroski
Journal:  J Virol       Date:  1993-08       Impact factor: 5.103

6.  Inter- and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic serotypes.

Authors:  J P Moore; Y Cao; J Leu; L Qin; B Korber; D D Ho
Journal:  J Virol       Date:  1996-01       Impact factor: 5.103

7.  Association of host cell surface adhesion receptors and other membrane proteins with HIV and SIV.

Authors:  R J Orentas; J E Hildreth
Journal:  AIDS Res Hum Retroviruses       Date:  1993-11       Impact factor: 2.205

8.  Synergistic neutralization of human immunodeficiency virus type 1 by combinations of human monoclonal antibodies.

Authors:  S Laal; S Burda; M K Gorny; S Karwowska; A Buchbinder; S Zolla-Pazner
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Primary isolates of human immunodeficiency virus type 1 are relatively resistant to neutralization by monoclonal antibodies to gp120, and their neutralization is not predicted by studies with monomeric gp120.

Authors:  J P Moore; Y Cao; L Qing; Q J Sattentau; J Pyati; R Koduri; J Robinson; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

10.  Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1.

Authors:  M Saifuddin; C J Parker; M E Peeples; M K Gorny; S Zolla-Pazner; M Ghassemi; I A Rooney; J P Atkinson; G T Spear
Journal:  J Exp Med       Date:  1995-08-01       Impact factor: 14.307

View more
  11 in total

1.  The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.

Authors:  Miroslaw K Gorny; Kathy Revesz; Constance Williams; Barbara Volsky; Mark K Louder; Christopher A Anyangwe; Chavdar Krachmarov; Samuel C Kayman; Abraham Pinter; Arthur Nadas; Phillipe N Nyambi; John R Mascola; Susan Zolla-Pazner
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

2.  Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.

Authors:  Nina R Derby; Zane Kraft; Elaine Kan; Emma T Crooks; Susan W Barnett; Indresh K Srivastava; James M Binley; Leonidas Stamatatos
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  SERINC5 Inhibits HIV-1 Infectivity by Altering the Conformation of gp120 on HIV-1 Particles.

Authors:  Austin Featherstone; Christopher Aiken
Journal:  J Virol       Date:  2020-09-29       Impact factor: 5.103

4.  Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.

Authors:  Tommy Tong; Keiko Osawa; James E Robinson; Ema T Crooks; James M Binley
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

5.  A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils.

Authors:  Mark Duval; Marshall R Posner; Lisa A Cavacini
Journal:  J Virol       Date:  2008-02-13       Impact factor: 5.103

6.  Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.

Authors:  T Beaumont; A van Nuenen; S Broersen; W A Blattner; V V Lukashov; H Schuitemaker
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

7.  N-terminal substitutions in HIV-1 gp41 reduce the expression of non-trimeric envelope glycoproteins on the virus.

Authors:  Antu K Dey; Kathryn B David; Neelanjana Ray; Thomas J Ketas; Per J Klasse; Robert W Doms; John P Moore
Journal:  Virology       Date:  2007-11-26       Impact factor: 3.616

8.  Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425A1g8.

Authors:  Xiaocong Yu; Mark Duval; Christopher Lewis; Melissa A Gawron; Rijian Wang; Marshall R Posner; Lisa A Cavacini
Journal:  J Immunol       Date:  2012-11-26       Impact factor: 5.422

9.  Humoral responses to HIVconsv induced by heterologous vaccine modalities in rhesus macaques.

Authors:  Nicola J Borthwick; Maximillian Rosario; Torben Schiffner; Emma Bowles; Tina Ahmed; Peter Liljeström; Guillaume E Stewart-Jones; Jan W Drijfhout; Cornelis J M Melief; Tomáš Hanke
Journal:  Immun Inflamm Dis       Date:  2015-03-11

10.  Overcoming the Constraints of Anti-HIV/CD89 Bispecific Antibodies That Limit Viral Inhibition.

Authors:  Xiaocong Yu; Mark Duval; Melissa Gawron; Marshall R Posner; Lisa A Cavacini
Journal:  J Immunol Res       Date:  2016-06-22       Impact factor: 4.818

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.